Wolfe Research starts Gilead at Outperform on ‘multiple shots on goal’
Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been ...
Gilead initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Published first on TheFly – the ...
Gilead Sciences: Approaching Overvalued
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
3 Spectacular High-Yield Dividend Stocks to Buy in November
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Seeking Alpha6d
Gilead Sciences: Finally Some Real Momentum
A mere $20 stock of Gilead in 2011 saw a considerable momentum in the years ... as investors could look forward to impressive ...